Dimensional Fund Advisors LP Raises Holdings in Bausch Health Cos Inc. $BHC

Dimensional Fund Advisors LP grew its stake in shares of Bausch Health Cos Inc. (NYSE:BHC) by 10.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,604,818 shares of the company’s stock after acquiring an additional 350,823 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Bausch Health Cos were worth $19,456,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caption Management LLC increased its position in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after acquiring an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in Bausch Health Cos by 12,589.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after acquiring an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Bausch Health Cos by 6,661.2% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC acquired a new position in shares of Bausch Health Cos in the fourth quarter valued at about $59,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Trading Up 5.5%

Shares of NYSE:BHC opened at $6.24 on Friday. Bausch Health Cos Inc. has a 12-month low of $4.33 and a 12-month high of $8.69. The company has a market capitalization of $2.33 billion, a PE ratio of -2.11 and a beta of 0.38. The business has a 50 day moving average of $5.09 and a two-hundred day moving average of $5.44. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $0.96 by $0.30. The business had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. As a group, analysts forecast that Bausch Health Cos Inc. will post 4.24 EPS for the current year.

Insider Activity

In related news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the sale, the director directly owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Royal Bank Of Canada reduced their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research note on Monday, April 27th. Weiss Ratings upgraded shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Zacks Research cut shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.